Dyne Therapeutics Prices Upsized $375M Public Offering at $20.50/Share, Extending Cash Runway into Q2 2028
DYN has more than doubled off its 52-week low of $8.88 on elevated volume (4.7× avg).
Summary
Dyne Therapeutics priced an upsized $375 million public offering at $20.50 per share, a 12% discount to market, extending its cash runway into Q2 2028 and funding its neuromuscular disease pipeline through key regulatory milestones.
Key Events · Financing and Capital Events · DYN
-
Upsized $375M Public Offering Priced
Dyne priced 18.3 million shares at $20.50 per share, a 12% discount to the prior close, raising gross proceeds of $375 million — a 25% increase from the initially filed $300 million offering.
-
Net Proceeds and Cash Runway Extension
Net proceeds are estimated at $352.1 million (or $405.0 million if the underwriters' option is fully exercised). Combined with existing cash and a recent $50 million debt draw, the company expects its cash runway to extend into Q2 2028.
-
Funding Through Key Catalysts
The extended runway carries Dyne past the FDA's Priority Review decision on z-rostudirsen for Duchenne muscular dystrophy, with a PDUFA date expected in late 2026 or early 2027, and supports ongoing Phase 3 and preclinical programs.
-
Dilution Impact
The offering represents approximately 11% dilution to existing shareholders based on the company's ~165 million shares outstanding, though the upsized deal and discount reflect strong institutional demand for the neuromuscular pipeline.
Analysis · DYN · Life Sciences
Dyne Therapeutics priced an upsized public offering of 18.3 million shares at $20.50 per share, a 12% discount to yesterday's close, raising gross proceeds of $375 million. The deal was increased from the $300 million initially filed, reflecting strong institutional demand. Net proceeds of approximately $352 million, combined with existing cash and a recent $50 million debt draw, extend the company's cash runway into the second quarter of 2028 — past key catalysts including the FDA decision on z-rostudirsen for Duchenne muscular dystrophy. The offering is dilutive to existing shareholders but provides critical funding to advance a broad neuromuscular pipeline.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 35.6% of the 1100 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DYN was trading at $23.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.8B. The 52-week trading range was $8.88 to $25.00. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.